BioHarvest Sciences (8MV0) Stock Price & Analysis
8MV0 Stock Chart & Stats
- Day’s Range
- EUR 1.36 - EUR 1.44
- 52-Week Range
- EUR 1.10 - EUR 7.95
- Previous Close
- EUR 1.31
- Volume
- N/A
- Average Volume (3M)
- 24
- Market Cap
- EUR 31.66M
- Enterprise Value
- EUR 66.16M
- Total Cash (Recent Filing)
- EUR 16.22M
- Total Debt (Recent Filing)
- EUR 17.55M
- Price to Earnings (P/E)
- ―
- Beta
- 0.94
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin
Rapid revenue expansion alongside a gross margin near 59% indicates improving commercial traction and attractive product economics. If maintained as sales scale, this gross profit profile can provide resources to fund development, strengthen market positioning, and support eventual operating leverage.
CDMO Commercial Expansion
The first major CDMO manufacturing agreement broadens BioHarvest beyond its VINIA consumer base and creates a pathway toward recurring manufacturing revenue. The contract also validates potential applications for its plant-cell platform in premium fragrance markets and supports longer-term scale.
Improved Liquidity
The substantial year-over-year increase in cash and deposits gives BioHarvest greater capacity to fund technology development, CDMO preparation, and commercial operations. Stronger liquidity also provides more flexibility while the company works toward sustained operating profitability.
Bears Say
Persistent Unprofitability
BioHarvest has not yet converted attractive gross economics into sustainable earnings, as net income, operating profit, and EBITDA remain negative. Continued losses can constrain reinvestment, require external funding, and leave execution dependent on successful scaling of newer opportunities.
Ongoing Cash Burn
Negative operating and free cash flow show that the current business still consumes cash to support operations and investment. Until cash generation turns sustainably positive, liquidity may be pressured by growth spending and the company may have less flexibility to absorb execution setbacks.
Lowered 2026 Outlook
The reduced 2026 outlook indicates weaker near-term commercial momentum and a less profitable VINIA trajectory than previously expected. Management is reallocating resources toward CDMO capacity, but that strategy increases dependence on future execution while current earnings remain under pressure.
BioHarvest Sciences News
8MV0 FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
What is BioHarvest Sciences’s market cap?
When is BioHarvest Sciences’s upcoming earnings report date?
How were BioHarvest Sciences’s earnings last quarter?
Is BioHarvest Sciences overvalued?
Does BioHarvest Sciences pay dividends?
What is BioHarvest Sciences’s EPS estimate?
How many shares outstanding does BioHarvest Sciences have?
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioHarvest Sciences?
What is the TipRanks Smart Score and how is it calculated?
BioHarvest Sciences Stock Smart Score
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
- Sector
- Consumerdefensive
- Industry
- Agricultural - Commodities/Milling
- CEO
- Zaki Rakib
- Employees
- 89
- Website
- www.bioharvest.com
- Address
- 1140-625 Howe Street, Vancouver, BC, V6C 2T6, CA
BioHarvest Sciences (8MV0) Earnings & Revenues
8MV0 Earnings Call
Earnings Call SentimentNeutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.
View all DE:8MV0 earnings summaries8MV0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 3 | 0 | 9 |
